Sunday 18 October 2026
Export CYAD’s income statement to Excel — free account
Celyad SA
CYAD Healthcare Biotechnology
Celyad SA’s revenue for fiscal 2025 (year ended December 2025) was $23,800.00, down 88.2% from fiscal 2024.
Follow CYAD
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (28.30) | (41.94) | (54.44) | |
Capital Expenditures |
— | — | — | 0.88 | |
| Other line items | |||||
Cash ROIC |
0.00% | 1,600.95% | (377.05%) | (786.70%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
— | 0.89 | 1.20 | 2.96 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.32 | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 14 Oct 2026